The sentinel-node injection that exceeds the ALARA plan
A nuclear medicine technologist is preparing a 99mTc-sulfur colloid lymphoscintigraphy study for a 48-year-old woman with newly diagnosed breast cancer. The surgeon has asked for a four-quadrant periareolar injection of 0.5 mCi (18.5 MBq) total, given as four 0.125 mCi aliquots, 2 hours before surgery. The department's written protocol specifies a single intradermal injection of 0.1 mCi (3.7 MBq) with imaging at 30 minutes and 2 hours. The technologist pages the authorized user (a nuclear medicine physician) and says the surgeon is insisting on the higher activity and the four-quadrant technique because "that's how we always do it." The physician is in another building and asks the physicist, who happens to be on site, to advise.
1. What are the dosimetry and radiation-safety considerations that bear on whether to accept the surgeon's request, and how do you frame the advice?
Read the worked answer
Frame this as a protocol-variance question, not a turf question. The relevant considerations:
- Dose to the technologist and OR staff. The injected activity is ~5x the protocol. The dominant occupational dose in lymphoscintigraphy is from the injection itself (hand dose) and from the patient during imaging and surgery. Hand dose scales roughly with activity handled and with time in proximity. A 5x activity increase, even with shielding and a syringe shield, materially increases extremity dose if the same technique is used.
- Patient dose. 99mTc-sulfur colloid has a small particle size and is cleared by the reticuloendothelial system; the effective dose per MBq is low, but 5x activity is still 5x the committed dose. For a patient with a new cancer diagnosis, this is a secondary consideration but should be stated honestly.
- ALARA and the department's license/protocol. The written protocol is the institution's ALARA instrument. Deviating requires an authorized-user decision and documentation, not a verbal request relayed through a technologist.
- Image quality and surgical utility. Higher activity and four-quadrant injection can improve count statistics and drainage mapping, but the surgeon's stated reason ("that's how we always do it") is not a technical justification. Ask what problem the current protocol is failing to solve.
The physicist should not overrule the authorized user or the surgeon. The correct action is to provide the dosimetry framing and route the decision to the authorized user, who owns the protocol.
2. The authorized user approves the variance by phone. What documentation and practical safeguards should accompany it?
Read the worked answer
A phone approval is acceptable only if it is captured in a retrievable record. Required elements:
- Written order and rationale in the patient record: the activity, the injection technique, the clinical reason, and the name of the approving authorized user with date and time.
- Protocol variance entry in the department's log, with a plan to review it at the next protocol committee meeting.
- Technologist briefing on the higher-activity handling: use a syringe shield, minimize time holding the syringe, pre-draw behind shielding, and use tongs or a shielded carrier for transport.
- OR communication: notify the surgical team of the actual activity and timing so they can plan their own dose-reduction measures (distance, lead apron, limited time near the injection site).
- Imaging timing: with 5x activity, the 30-minute and 2-hour images may be overexposed or saturate; adjust acquisition time or collimator choice rather than accepting a degraded study.
- Post-procedure review: compare the node identification rate and any extravasation or failed mapping against the standard protocol.
The judgment point: the physicist's role is to make the consequences visible and to ensure the variance is documented and reviewed, not to silently absorb a verbal request.